Table 2.
KEGG pathway gene set enrichment analysis of GLI genes
| KEGG pathway enriched terms for GLI1 gene | ||||||||
|---|---|---|---|---|---|---|---|---|
| S. no. | Gene set | Description | Size | Leading edge number | ES | NES | p value | FDR |
| 1 | hsa04340 | Hedgehog signaling pathway | 44 | 15 | 0.76588 | 2.3562 | 0 | 0 |
| 2 | hsa05217 | Basal cell carcinoma | 63 | 19 | 0.72193 | 2.3328 | 0 | 0 |
| 3 | hsa04392 | Hippo signaling pathway | 25 | 11 | 0.76573 | 2.0433 | 0 | 0 |
| 4 | hsa04330 | Notch signaling pathway | 48 | 18 | 0.61991 | 1.9108 | 0 | 0.0029577 |
| 5 | hsa04350 | TGF-beta signaling pathway | 83 | 21 | 0.55111 | 1.8568 | 0 | 0.0074364 |
| 6 | hsa05200 | Pathways in cancer | 513 | 112 | 0.43313 | 1.7604 | 0 | 0.021488 |
| 7 | hsa05224 | Breast cancer | 145 | 41 | 0.48757 | 1.7515 | 0 | 0.021549 |
| 8 | hsa05206 | MicroRNAs in cancer | 149 | 53 | 0.43962 | 1.5859 | 0 | 0.057002 |
| 9 | hsa04520 | Adherens junction | 66 | 21 | 0.53756 | 1.7326 | 0.0029326 | 0.025727 |
| 10 | hsa05205 | Proteoglycans in cancer | 196 | 57 | 0.44600 | 1.6662 | 0.0025316 | 0.040692 |
| 11 | hsa05226 | Gastric cancer | 147 | 37 | 0.45157 | 1.6389 | 0 | 0.042948 |
| 12 | hsa03030 | DNA replication | 36 | 16 | 0.56410 | 1.6319 | 0.0032680 | 0.043004 |
| 13 | hsa04064 | NF-kappa B signaling pathway | 90 | 27 | 0.48123 | 1.6420 | 0.0027778 | 0.043309 |
| 14 | hsa04310 | Wnt signaling pathway | 143 | 27 | 0.44741 | 1.6105 | 0.0027701 | 0.050169 |
| 15 | hsa05219 | Bladder cancer | 40 | 6 | 0.52904 | 1.5848 | 0.012987 | 0.055332 |
| 16 | hsa05212 | Pancreatic cancer | 75 | 13 | 0.48239 | 1.5762 | 0.0058480 | 0.055773 |
| 17 | hsa05168 | Herpes simplex infection | 167 | 52 | 0.43152 | 1.5922 | 0 | 0.056176 |
| 18 | hsa05222 | Small cell lung cancer | 92 | 26 | 0.49563 | 1.7174 | 0 | 0.026427 |
| 19 | hsa03440 | Homologous recombination | 34 | 19 | 0.60408 | 1.7233 | 0 | 0.026703 |
| 20 | hsa04512 | ECM–receptor interaction | 80 | 38 | 0.50174 | 1.7029 | 0.0031056 | 0.029154 |
| KEGG pathway enriched terms for GLI2 gene | ||||||||
| 1 | hsa04340 | Hedgehog signaling pathway | 44 | 11 | 0.73938 | 2.132 | 0 | 0 |
| 2 | hsa05217 | Basal cell carcinoma | 63 | 14 | 0.66646 | 2.115 | 0 | 0 |
| 3 | hsa03440 | Homologous recombination | 34 | 21 | 0.71827 | 2.0073 | 0 | 0.00052273 |
| 4 | hsa04330 | Notch signaling pathway | 48 | 21 | 0.66048 | 1.9594 | 0 | 0.0019602 |
| 5 | hsa03030 | DNA replication | 36 | 12 | 0.66881 | 1.9075 | 0 | 0.00345 |
| 6 | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 137 | 34 | 0.48551 | 1.7009 | 0 | 0.027287 |
| 7 | hsa05224 | Breast cancer | 145 | 35 | 0.47901 | 1.6679 | 0.0032787 | 0.034762 |
| 8 | hsa05206 | MicroRNAs in cancer | 149 | 36 | 0.46984 | 1.6751 | 0 | 0.035783 |
| 9 | hsa05200 | Pathways in cancer | 513 | 94 | 0.39602 | 1.568 | 0 | 0.083604 |
| 10 | hsa05213 | Endometrial cancer | 58 | 16 | 0.49222 | 1.5323 | 0.014706 | 0.11429 |
| 11 | hsa04512 | ECM–receptor interaction | 80 | 25 | 0.46807 | 1.5184 | 0.020134 | 0.11506 |
| 12 | hsa04064 | NF-kappa B signaling pathway | 90 | 26 | 0.46032 | 1.5239 | 0.010033 | 0.11518 |
| 13 | hsa05168 | Herpes simplex infection | 167 | 55 | 0.42315 | 1.5002 | 0 | 0.12277 |
| 14 | hsa00514 | Other types of O-glycan biosynthesis | 17 | 5 | 0.60163 | 1.4613 | 0.064 | 0.15566 |
| 15 | hsa05222 | Small cell lung cancer | 92 | 27 | 0.44044 | 1.4515 | 0.013333 | 0.15789 |
| 16 | hsa04390 | Hippo signaling pathway | 148 | 30 | 0.4473 | 1.5822 | 0 | 0.076528 |
| 17 | hsa04919 | Thyroid hormone signaling pathway | 116 | 41 | 0.46405 | 1.5904 | 0 | 0.076282 |
| 18 | hsa04520 | Adherens junction | 66 | 17 | 0.51313 | 1.6179 | 0 | 0.060918 |
| 19 | hsa03430 | Mismatch repair | 23 | 13 | 0.72021 | 1.8379 | 0 | 0.0058807 |
| 20 | hsa00310 | Lysine degradation | 44 | 18 | 0.61666 | 1.8299 | 0.0037453 | 0.0054016 |
| KEGG pathway enriched terms for GLI3 gene | ||||||||
| 1 | hsa04340 | Hedgehog signaling pathway | 44 | 14 | 0.71731 | 2.0981 | 0 | 0 |
| 2 | hsa05217 | Basal cell carcinoma | 63 | 21 | 0.64393 | 1.9710 | 0 | 0 |
| 3 | hsa04330 | Notch signaling pathway | 48 | 18 | 0.67135 | 1.9548 | 0 | 0.00064215 |
| 4 | hsa04392 | Hippo signaling pathway | 25 | 15 | 0.72990 | 1.9029 | 0 | 0.0028897 |
| 5 | hsa05206 | MicroRNAs in cancer | 149 | 51 | 0.53318 | 1.8553 | 0 | 0.0050088 |
| 6 | hsa05224 | Breast cancer | 145 | 38 | 0.52266 | 1.8394 | 0 | 0.0054583 |
| 7 | hsa04919 | Thyroid hormone signaling pathway | 116 | 27 | 0.54149 | 1.8153 | 0 | 0.0074306 |
| 8 | hsa00310 | Lysine degradation | 44 | 16 | 0.61774 | 1.7906 | 0.0038023 | 0.0098730 |
| 9 | hsa03440 | Homologous recombination | 34 | 19 | 0.64132 | 1.7623 | 0.0042553 | 0.013057 |
| 10 | hsa05205 | Proteoglycans in cancer | 196 | 61 | 0.46161 | 1.6748 | 0 | 0.029193 |
| 11 | hsa03430 | Mismatch repair | 23 | 12 | 0.65758 | 1.6798 | 0 | 0.029539 |
| 12 | hsa04512 | ECM–receptor interaction | 80 | 31 | 0.52651 | 1.6809 | 0 | 0.031874 |
| 13 | hsa03460 | Fanconi anemia pathway | 44 | 19 | 0.56253 | 1.6403 | 0 | 0.035832 |
| 14 | hsa05215 | Prostate cancer | 96 | 29 | 0.48765 | 1.6216 | 0 | 0.038416 |
| 15 | hsa01522 | Endocrine resistance | 94 | 19 | 0.49222 | 1.6267 | 0 | 0.038649 |
| 16 | hsa00562 | Inositol phosphate metabolism | 74 | 32 | 0.50385 | 1.6104 | 0.0040816 | 0.039239 |
| 17 | hsa05200 | Pathways in cancer | 513 | 104 | 0.40837 | 1.6123 | 0 | 0.040134 |
| 18 | hsa05226 | Gastric cancer | 147 | 52 | 0.45184 | 1.5986 | 0 | 0.040547 |
| 19 | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 137 | 62 | 0.46230 | 1.5875 | 0 | 0.045184 |
| 20 | hsa04360 | Axon guidance | 173 | 55 | 0.42350 | 1.5115 | 0 | 0.089901 |